Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Eur J Cancer

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

Published: September 2018

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.ejca.2018.06.002	DOI Listing

Publication Analysis

corrigendum 'ramucirumab

'ramucirumab second-line

second-line treatment

treatment patients

patients advanced

advanced hepatocellular

hepatocellular carcinoma

carcinoma first-line

first-line therapy

therapy sorafenib

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!